DiaMedica Therapeutics (NASDAQ:DMAC) Stock Falls 1.6% – Time to Sell?
by Sarita Garza · The Markets DailyDiaMedica Therapeutics, Inc. (NASDAQ:DMAC – Get Free Report) shares traded down 1.6% during mid-day trading on Monday. The company traded as low as $7.95 and last traded at $8.20. Approximately 185,580 shares traded hands during mid-day trading, a decline of 20% from the average session volume of 232,278 shares. The stock had previously closed at $8.33.
Analyst Ratings Changes
Several research analysts have recently commented on DMAC shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a research note on Friday, July 17th. HC Wainwright restated a “buy” rating and issued a $12.00 price target on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $12.00.
Read Our Latest Stock Analysis on DMAC
DiaMedica Therapeutics Trading Down 2.0%
The business’s 50 day moving average price is $7.12 and its 200-day moving average price is $6.68. The company has a market cap of $413.10 million, a price-to-earnings ratio of -10.64 and a beta of 0.92.
DiaMedica Therapeutics (NASDAQ:DMAC – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.19) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.01. Equities research analysts forecast that DiaMedica Therapeutics, Inc. will post -0.84 EPS for the current fiscal year.
Institutional Investors Weigh In On DiaMedica Therapeutics
Institutional investors have recently made changes to their positions in the company. AWM Investment Company Inc. acquired a new stake in DiaMedica Therapeutics during the 2nd quarter worth approximately $253,000. Bank of America Corp DE boosted its stake in DiaMedica Therapeutics by 62.5% in the 1st quarter. Bank of America Corp DE now owns 42,768 shares of the company’s stock valued at $290,000 after purchasing an additional 16,446 shares during the period. World Investment Advisors boosted its stake in DiaMedica Therapeutics by 7.7% in the 4th quarter. World Investment Advisors now owns 36,975 shares of the company’s stock valued at $294,000 after purchasing an additional 2,650 shares during the period. Renaissance Technologies LLC bought a new stake in DiaMedica Therapeutics in the 1st quarter valued at $356,000. Finally, Sei Investments Co. grew its holdings in DiaMedica Therapeutics by 100.0% in the 1st quarter. Sei Investments Co. now owns 111,320 shares of the company’s stock valued at $754,000 after buying an additional 55,660 shares in the last quarter. Institutional investors own 10.12% of the company’s stock.
About DiaMedica Therapeutics
DiaMedica Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for serious diseases affecting the kidneys and nervous system. The company’s research is centered on biological pathways that may support tissue protection and recovery in conditions with limited treatment options.
Its lead investigational product, DM199, is a recombinant form of human tissue kallikrein-1, an enzyme involved in the kallikrein-kinin system. DiaMedica has studied DM199 in acute ischemic stroke and kidney-related disorders, including severe acute kidney injury.